| 王少雷,魏 宏,刘德华,史国栋,吴丽娜.肝动脉化疗栓塞联合射频消融对中晚期肝癌患者血清肿瘤活性因子、肝功能和预后的影响[J].,2020,(7):1293-1296 |
| 肝动脉化疗栓塞联合射频消融对中晚期肝癌患者血清肿瘤活性因子、肝功能和预后的影响 |
| Effects of Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation on Serum Tumor Activity Factor, Liver Function and Prognosis in Patients with Advanced Hepatocellular Carcinoma |
| 投稿时间：2019-07-28 修订日期：2019-08-23 |
| DOI：10.13241/j.cnki.pmb.2020.07.019 |
| 中文关键词: 肝动脉化疗栓塞 射频消融 中晚期 肝癌 肿瘤活性因子 肝功能 预后 |
| 英文关键词: Transcatheter arterial chemoembolization Radiofrequency ablation Advanced Liver cancer Tumor active factor Liver function Prognosis |
| 基金项目:辽宁省临床能力建设项目（LNCCC-D47-2015） |
|
| 摘要点击次数: 832 |
| 全文下载次数: 370 |
| 中文摘要: |
| 摘要 目的：探讨肝动脉化疗栓塞（TACE）联合射频消融（RFA）对中晚期肝癌患者血清肿瘤活性因子、肝功能和预后的影响。方法：选取2012年2月~2016年6月期间我院收治的中晚期肝癌患者103例，根据随机数字表法将患者分为对照组（n=51）和研究组（n=52），对照组患者给予RFA治疗，研究组给予TACE联合RFA治疗，比较两组临床总有效率，比较两组治疗前后肝功能、血清肿瘤活性因子水平，统计两组患者并发症情况和预后。结果：治疗后研究组临床总有效率为53.85%（28/52），高于对照组患者的33.33%（17/51）（P<0.05）。两组患者治疗后总胆红素（TBIL）、丙氨酸转氨酶（ALT）、氨基酸转氨酶（AST）较治疗前降低（P<0.05），但两组治疗后TBIL、ALT、AST比较差异无统计学意义（P>0.05）。两组患者治疗后甲胎蛋白（AFP）、糖类抗原199（CA199），基质金属蛋白酶（MMP）均较治疗前降低，且研究组低于对照组（P<0.05）。两组患者并发症发生率比较无差异（P>0.05）。研究组患者治疗后1年、2年复发率低于对照组，生存率高于对照组（P<0.05）。结论：TACE联合RFA治疗中晚期肝癌，疗效确切，可有效降低血清肿瘤活性因子水平，未加重肝功能损伤，且可改善患者的预后。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) on serum tumor activity factors, liver function and prognosis in patients with advanced hepatocellular carcinoma. Methods: 103 patients with advanced hepatocellular carcinoma who were admitted to our hospital from February 2012 to June 2016 were selected, they were randomly divided into control group (n=51) and study group (n=52), the control group was treated with RFA, and the study group was treated with TACE combined with RFA. The clinical total effective rate was compared between the two groups. Liver function and serum levels of tumor active factors in two groups were compared before and after treatment. The complications and prognosis of the two groups were observed. Results: After treatment, the total clinical effective rate of the study group was 53.85% (28/52), which was significantly higher than that of the control group 33.33% (17/51)(P<0.05). After treatment, total bilirubin (TBIL), Alanine aminotransferase (ALT) and amino acid aminotransferase (AST) were lower than those before treatment (P<0.05), but there were no significant differences in TBIL, ALT and AST between the two groups (P>0.05). After treatment, the alpha-fetoprotein (AFP), carbohydrate antigen 199 (CA199) and matrix metalloproteinase (MMP) in both groups were lower than those before treatment, and those in the study group were lower than those in the control group (P<0.05). There was no significant difference in the incidence of complications between the two groups(P>0.05). The recurrence rate of 1 year and 2 years after treatment in the study group was lower than that in the control group, and the survival rate was higher than that in the control group (P<0.05). Conclusion: TACE combined with RFA is effective in the treatment of advanced hepatocellular carcinoma. It can effectively reduce the level of serum tumor active factors, without aggravating liver function damage, and improve the prognosis of patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
